Lantern Pharma Achieves Key Enrollment Milestone in Japan for Never-Smoker Lung Cancer Trial

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC™ clinical trial. The trial evaluates investigational drug candidate LP-300 in never-smoker non-small cell lung cancer (NSCLC) patients, representing a significant milestone in the company's international expansion strategy.

According to company leadership, the completion of enrollment in Japan ahead of schedule demonstrates excellent execution of their global approach. Lantern Pharma CEO and President Panna Sharma stated that this achievement validates the company's decision to focus on regions where never-smoker NSCLC has the highest prevalence. The company's progress in Japan builds momentum as enrollment continues in Taiwan and the United States, bringing the program closer to generating clinical data that could establish LP-300 as a treatment option for this underserved patient population.

Lantern Pharma's proprietary AI and machine learning platform, RADR®, leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to solve real-world problems in oncology drug development. The company has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. Additional information about the company's developments is available in their newsroom at https://ibn.fm/LTRN.

The Phase 2 HARMONIC™ trial represents an important advancement in addressing the significant unmet medical need among never-smoker lung cancer patients. This demographic represents a distinct patient population that often faces different disease characteristics and treatment challenges compared to smoking-related lung cancers. The successful enrollment in Japan, where never-smoker NSCLC prevalence is particularly high, provides valuable clinical data that could lead to new treatment paradigms for this specific patient group.

For investors and stakeholders following biotechnology developments, the latest news and updates relating to LTRN are available through the company's communications channels. The broader biomedical community can access specialized communications through platforms such as https://www.BioMedWire.com, which focuses on the latest developments in biotechnology, biomedical sciences, and life sciences sectors.